NextPoint

aid: nextpoint
name: NextPoint
description: NextPoint Therapeutics, Inc. is a clinical-stage immuno-oncology biotechnology company headquartered at 238 Main
  Street, Cambridge, Massachusetts. Founded in 2019-2020 out of MPM Capital on discoveries by Gordon Freeman (Dana-Farber
  Cancer Institute) and XingXing Zang (Albert Einstein College of Medicine), it develops first-in-class precision therapeutics
  against the B7-H7/HHLA2 - KIR3DL3 immune checkpoint axis, combining direct tumor-cell killing with immunomodulation in a
  single molecule. Its pipeline spans three modalities - NPX887, an anti-B7-H7 monoclonal antibody with TMIGD2 co-stimulation
  and enhanced ADCC currently in Phase 1; NPX372, a 2:1 bispecific B7-H7 x CD3 T cell engager; and NPX125, a DAR8 antibody
  drug conjugate - all guided by a biomarker-driven patient selection strategy. Investors include Leaps by Bayer, Sanofi Ventures,
  MPM BioImpact, Catalio Capital, Dana-Farber, Invus, Arkin, Simcere, SixtyDegree and Pagoda Tree; its shares trade on private
  secondary marketplaces. It is a therapeutics developer rather than a software company and publishes no API, SDK, developer
  program or machine-readable specification.
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: false
  label: Hosted service · you call their endpoint
  confidence: medium
  source:
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://nextpointtx.com/wp-content/uploads/2025/08/logo-nextpoint.png
url: https://raw.githubusercontent.com/api-evangelist/nextpoint/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-source-url: https://forgeglobal.com/nextpoint_stock/
specificationVersion: '0.23'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Immunotherapy
- Precision Medicine
- Clinical Stage
- Drug Development
- Healthcare
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/nextpoint-domain-security.yml
- type: Website
  url: https://nextpointtx.com/
- type: About
  url: https://nextpointtx.com/about-us/
- type: News
  url: https://nextpointtx.com/news-publications/
- type: PrivacyPolicy
  url: https://nextpointtx.com/privacy-policy/
- type: TermsOfService
  url: https://nextpointtx.com/terms-of-use/
- type: LinkedIn
  url: https://www.linkedin.com/company/nextpoint-therapeutics
x-enrichment:
  date: '2026-08-26'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: NextPoint Therapeutics is a clinical-stage oncology drug developer whose entire public surface is a seven-page WordPress
    marketing site (home, about, pipeline, science, news, terms, privacy) with no developer, API or documentation section;
    api./developer./docs./ portal./app./mcp.nextpointtx.com do not resolve in DNS, no GitHub organization exists under nextpointtx
    or nextpoint-therapeutics, and every spec path returns the site's 158,191-byte homepage catch-all byte-identical to a
    nonsense control URL.
  evidence:
  - url: https://nextpointtx.com/openapi.json
    status: 200
  - url: https://nextpointtx.com/llms.txt
    status: 404
  - url: https://nextpointtx.com/.well-known/security.txt
    status: 404
  - url: https://nextpointtx.com/.well-known/agent-card.json
    status: 200
  - url: https://api.github.com/orgs/nextpoint-therapeutics
    status: 404
  - url: https://nextpointtx.com/about-us/
    status: 200
  checked: '2026-08-26'